Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylprednisolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.65 |
| ▸ | PGR | P06401 | 7/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | AR | P10275 | 3/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | IL6 | P05231 | 1/20 | 0.48 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.48 |
| ▸ | GLUL | P15104 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylprednisolone SCHEMBL12440040 | 0.81 | HIF1A (1.00) | NR3C1PGRCYP3A4HIF1AHSD17B10 | |
| Methylprednisolone SCHEMBL13046609 | 0.81 | HIF1A (1.00) | NR3C1PGRCYP3A4HIF1AHSD17B10 | |
| Methylprednisolone SCHEMBL5084 | 0.81 | HIF1A (1.00) | NR3C1PGRCYP3A4HIF1AHSD17B10 | |
| Methylprednisolone SCHEMBL16221544 | 0.81 | HIF1A (1.00) | NR3C1PGRCYP3A4HIF1AHSD17B10 | |
| Methylprednisolone SCHEMBL19327123 | 0.81 | HIF1A (1.00) | NR3C1PGRCYP3A4HIF1AHSD17B10 | |
| Methylprednisolone SCHEMBL193216 | 0.81 | HIF1A (1.00) | NR3C1PGRCYP3A4HIF1AHSD17B10 | |
| Methylprednisolone SCHEMBL10393322 | 0.81 | HIF1A (1.00) | NR3C1PGRCYP3A4HIF1AHSD17B10 | |
| Methylprednisolone SCHEMBL7160264 | 0.81 | HIF1A (1.00) | NR3C1PGRCYP3A4HIF1AHSD17B10 | |
| Methylprednisolone SCHEMBL21145528 | 0.81 | HIF1A (1.00) | NR3C1PGRCYP3A4HIF1AHSD17B10 | |
| Methylprednisolone SCHEMBL143076 | 0.81 | HIF1A (1.00) | NR3C1PGRCYP3A4HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786523-B2 | Composition and method for reducing thrombocytopenia | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220143013-A1 | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA | BEYONDSPRING PHARMACEUTICALS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11229642-B2 | Composition and method for reducing neutropenia | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210046068-A1 | COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA | BEYONDSPRING PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210030843-A1 | COMPOSITION AND METHOD FOR REDUCING CHEMOTHERAPY-INDUCED NEUTROPENIA VIA THE ADMINISTRATION OF PLINABULIN AND A G-CSF AGENT | BEYONDSPRING PHARMACEUTICALS, INC. | 2021-02-04 | — | — | US | disclosed |
| CN-112135614-A | Compositions and methods for reducing thrombocytopenia by administering plinabulin | 大连万春布林医药有限公司 | 2020-12-25 | — | — | CN | disclosed |
| EP-3746076-A1 | COMPOSITION AND METHOD FOR REDUCING CHEMOTHERAPY-INDUCED NEUTROPENIA VIA THE ADMINISTRATION OF PLINABULIN AND A G-CSF AGENT | Beyondspring Pharmaceuticals Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3743074-A1 | COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA VIA THE ADMINISTRATION OF PLINABULIN | Beyondspring Pharmaceuticals Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200038395-A1 | METHOD OF REDUCING NEUTROPENIA | BEYONDSPRING PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| CN-110381938-A | The method for reducing neutrophil leucocyte deficiency disease | 大连万春布林医药有限公司 | 2019-10-25 | — | — | CN | disclosed |
| WO-2019152530-A1 | COMPOSITION AND METHOD FOR REDUCING CHEMOTHERAPY-INDUCED NEUTROPENIA VIA THE ADMINISTRATION OF PLINABULIN AND A G-CSF AGENT | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019147615-A1 | COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA VIA THE ADMINISTRATION OF PLINABULIN | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20190175587-A1 | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA | BEYONDSPRING PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
| EP-3463337-A1 | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA | Beyondspring Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2018144764-A1 | METHOD OF REDUCING NEUTROPENIA | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2017214052-A1 | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |